Literature DB >> 16530893

Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.

K Suwansrinon1, H Wilde, M Benjavongkulchai, U Banjongkasaena, S Lertjarutorn, S Boonchang, R Suttisri, P Khowplod, S Daviratanasilpa, V Sitprija.   

Abstract

Physicians dealing with potential rabies exposures and travel medicine are frequently asked how long previous pre- or post-exposure rabies vaccination induced immunity persists. We therefore carried out a prospective study on 118 rabies vaccine recipients who had received pre- or post-exposure regimens with tissue culture rabies vaccines by intramuscular or intradermal schedules 5-21 years previously. Rabies neutralizing antibody was detectable in the sera of all subjects on day 0. They then received one intradermal 0.1 mL booster injection on days 0 and 3. Neutralizing antibody determination was carried out on days 5, 7 and 14. All except one subject showed an accelerated antibody response following the two booster injections. Vaccination with a WHO recognized tissue culture rabies vaccine evokes long lasting immunity. This study supports current recommendations that immunity is long lasting and that boosters without immunoglobulin are sufficient even when prior vaccination was longer than 5 years previously.

Mesh:

Substances:

Year:  2006        PMID: 16530893     DOI: 10.1016/j.vaccine.2006.02.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Rabies in travelers.

Authors:  Philippe Gautret; Philippe Parola
Journal:  Curr Infect Dis Rep       Date:  2014-03       Impact factor: 3.725

2.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Authors:  Ashwath Narayana; Aravind Manoharan; Madhusudana Shampur Narayan; Sudarshan Mysore Kalappa; Gangaboraiah Biligumba; Ravish Haradanahalli; Ashwini Manoor Anand
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

5.  Pre-exposure prophylaxis against rabies in children: safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route.

Authors:  Haradanahalli S Ravish; Jayanthi Srikanth; Doddabele Hanumanthaiah Ashwath Narayana; Rachana Annadani; Veena Vijayashankar; Malatesh Undi
Journal:  Hum Vaccin Immunother       Date:  2013-06-20       Impact factor: 3.452

6.  Using intradermal rabies vaccine to boost immunity in people with low rabies antibody levels.

Authors:  David Brown; Anthony R Fooks; Martin Schweiger
Journal:  Adv Prev Med       Date:  2011-05-25

7.  Reducing Cost of Rabies Post Exposure Prophylaxis: Experience of a Tertiary Care Hospital in Pakistan.

Authors:  Naseem Salahuddin; M Aftab Gohar; Naila Baig-Ansari
Journal:  PLoS Negl Trop Dis       Date:  2016-02-26

Review 8.  Guidelines for the prevention of travel-associated illness in older adults.

Authors:  Tida K Lee; Jack N Hutter; Jennifer Masel; Christie Joya; Timothy J Whitman
Journal:  Trop Dis Travel Med Vaccines       Date:  2017-06-13

9.  Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.

Authors:  Y Bui; M Sow; E Cambron-Goulet; E Levac; F Milord
Journal:  Can Commun Dis Rep       Date:  2015-03-05

10.  Neutralizing Antibody Response after Intramuscular Purified Vero Cell Rabies Vaccination (PVRV) in Iranian Patients with Specific Medical Conditions.

Authors:  Pooneh Rahimi; RouhAllah Vahabpour; Mohammad Reza Aghasadeghi; Syed Mehdi Sadat; Nader Howaizi; Ehsan Mostafavi; Ali Eslamifar; Vida Fallahian
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.